A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.

MLA

Chen, Dongjian, et al. “A 5-Year Follow-up Clinical Study of the B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 17, Sept. 2024, pp. 3747–56. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-0414.

APA

Chen, D., Zhu, Y., Chen, Z., Jiang, S., He, H., Qiang, W., Xiang, F., Sun, X., & Du, J. (2024). A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(17), 3747–3756. https://doi.org/10.1158/1078-0432.CCR-24-0414

Chicago

Chen, Dongjian, Yu Zhu, Zhi Chen, Songfu Jiang, Haiyan He, Wanting Qiang, Fang Xiang, Xuedong Sun, and Juan Du. 2024. “A 5-Year Follow-up Clinical Study of the B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (17): 3747–56. doi:10.1158/1078-0432.CCR-24-0414.